Global monoclonal antibody therapeutics market expected to generate revenue of around USD 218.97 billion by the end of 2023, growing at a CAGR of around 12.5% between 2017 and 2023.
Monoclonal Antibody Therapeutics Market
The report covers forecast and analysis for the monoclonal antibody therapeutics market on a global and regional level. The study provides historic data of 2015 to 2017 along with a forecast from 2018 to 2023 based on revenue (218.97 USD Billion). The study includes drivers and restraints for the monoclonal antibody therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the monoclonal antibody therapeutics market on a global level.
In order to give the users of this report a comprehensive view on the monoclonal antibody therapeutics market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market.
The study provides a decisive view on the monoclonal antibody therapeutics market by segmenting the market based on application, source, end user and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2023. Based on application, the market is segmented into cancer, autoimmune diseases, infection, hematological diseases, and others. By source, the market is segmented into human, humanized, chimeric and others. Based on end users, the market is segmented into hospitals, private clinics and research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes demand for monoclonal antibody therapeutics market based on all segments in all the regions and countries.
|Monoclonal Antibody Therapeutics Market
|Market Size in 2017
|USD 108.01 Billion
|Market Forecast in 2023
|USD 218.97 Billion
|Compound Annual Growth Rate
|CAGR of 12.5%
|Number of Pages
|Value (USD Billion), and Volume (Units)
|Key Companies Covered
|Pfizer Inc., Bayer AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, and AbbVie Inc.
|By Source, By Application, By End User And By Region
|North America, Europe, Asia Pacific (APAC), Latian America, Middle East and Africa (MEA)
|North America: U.S and Canada
Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
Latin America: Brazil, Argentina, Chile
The Middle East And Africa: South Africa, GCC, Rest of MEA
|2015 to 2017
|2017 - 2023
|Avail customized purchase options to meet your exact research needs. Request For Customization
The report also includes detailed profiles of end players such as Pfizer Inc., Bayer AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, and AbbVie Inc.
Global Monoclonal Antibody Therapeutics Market: Application Segment Analysis
Global Monoclonal Antibody Therapeutics Market: Source Segment Analysis
Global Monoclonal Antibody Therapeutics Market: End User Segment Analysis
Global Monoclonal Antibody Therapeutics Market: Regional Segment Analysis
Monoclonal antibodies (mAbs) are laboratory-produced proteins that mimic the immune system's ability to fight off harmful pathogens, such as viruses or cancer cells. They are designed to target specific proteins or antigens on the surface of these cells and neutralize their activity.
The global monoclonal antibody therapeutics market was valued at approximately 108.01 Billion in 2017 and is projected to grow at a compound annual growth rate (CAGR) of around 12.5% from 2017 to 2023.
The main drivers of growth in the monoclonal antibody therapeutics market include increasing prevalence of chronic diseases, rising demand for personalized medicine, growing investments in research and development activities, and increasing adoption of mAbs in emerging markets.
Some of the major challenges faced by the monoclonal antibody therapeutics market include high costs associated with the development and manufacturing of these drugs, stringent regulatory requirements, and the emergence of biosimilars and other competing therapies.